Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CellSource Co., Ltd. ( (JP:4880) ) has shared an update.
CellSource Co., Ltd. operates in the medical and biotechnology services sector, focusing on contract processing of blood-derived products for clinical applications. Its primary business serves departments such as self-funded and hybrid orthopedics, OB&GYN, and aesthetic medicine, with a market focus on supporting medical institutions through processing services and related business support offerings.
The company reported a year-on-year increase in the daily average number of contract processing orders to 54.3 in January 2026, driven mainly by growth in hybrid orthopedics and OB&GYN, despite declines in self-funded orthopedics and aesthetic medicine. Monthly orders for blood-derived products fell 5.7% in self-funded orthopedics to 705 but rose 11.6% in hybrid orthopedics to 761, reflecting the impact of strengthened business support for medical corporations and targeted measures at key medical institutions, which suggest a shifting demand mix within its core healthcare markets.
The most recent analyst rating on (JP:4880) stock is a Hold with a Yen455.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the medical and biotechnology services sector, focusing on contract processing of blood-derived products for clinical applications. Its primary business serves departments such as self-funded and hybrid orthopedics, OB&GYN, and aesthetic medicine, with a market focus on supporting medical institutions through processing services and related business support offerings.
The company reported a year-on-year increase in the daily average number of contract processing orders to 54.3 in January 2026, driven mainly by growth in hybrid orthopedics and OB&GYN, despite declines in self-funded orthopedics and aesthetic medicine. Monthly orders for blood-derived products fell 5.7% in self-funded orthopedics to 705 but rose 11.6% in hybrid orthopedics to 761, reflecting the impact of strengthened business support for medical corporations and targeted measures at key medical institutions, which suggest a shifting demand mix within its core healthcare markets.
Average Trading Volume: 100,781
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.87B
See more insights into 4880 stock on TipRanks’ Stock Analysis page.